Memantine Use Should Be Restricted, U.K. Cost-Effectiveness Group Says

National Institute for Clinical Excellence recommends against using Lundbeck’s Ebixa (Forest’s Namenda in the U.S.) for treating moderately severe to severe Alzheimer’s disease. Group also recommends against use of acetylcholinesterase inhibitors for mild to moderate Alzheimer’s.